株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

製薬業の提携・ライセンス・投資・M&A取引と動向

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q2 2017

発行 GlobalData 商品コード 331738
出版日 ページ情報 英文 92 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.97円で換算しております。
Back to Top
製薬業の提携・ライセンス・投資・M&A取引と動向 Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q2 2017
出版日: 2017年08月14日 ページ情報: 英文 92 Pages
概要

当レポートでは、世界の製薬業の提携・ライセンス・M&A・資金調達に関する主要データと動向分析に焦点を当てて、過去5年間の取引件数と取引額 (取引タイプ・治療分野・地域別) について検証し、製薬業の投資顧問会社に関する情報も含めて、体系的な情報を提供しています。

第1章 目次

第2章 世界の製薬・医療市場:取引サマリー

  • 取引分析
  • タイプ別、取引件数
  • タイプ別、取引額
  • 主要取引
  • 主要取引サマリー

第3章 世界の製薬・医療市場:主要取引契約者

第4章 世界の製薬・医療市場:取引サマリー (タイプ別)

  • M&A
  • 株式発行取引
  • 債券発行取引
  • 提携取引
  • ライセンス契約
  • 未公開株式発行取引
  • ベンチャーキャピタル取引

第5章 世界の製薬・医療市場:取引サマリー (市場別)

  • 腫瘍
  • 中枢神経系
  • 感染症
  • 免疫系
  • 心血管系
  • 代謝障害
  • 消化管

第6章 製薬・医療市場:取引サマリー (地域別)

  • 北米
  • 欧州
  • アジア太平洋地域
  • その他の地域

第7章 世界の製薬・医療市場:主要投資顧問会社

  • M&A
  • 株式発行

第8章 その他の情報

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC0516QD

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q2 2017", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q2 2017. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

The pharmaceutical and healthcare industry reported a decrease in the number of deals and deal values in Q2 2017 with 1,110 deals worth USD91.3 billion, as compared 1,224 worth USD163.8 billion in Q2 2016. On a quarter-on-quarter basis, the number of deals and deal values decreased in Q2 2017, when compared to 1,185 deals worth USD95.9 billion in Q1 2017. The pharmaceutical and healthcare industry reported a decrease in upfront payments in licensing agreements with USD725.3m in Q2 2017, as compared USD1.1 billion in Q2 2016. On a quarter-on-quarter basis, the upfront payments reported a marginal increase in Q2 2017, when compared to USD723.6m in Q1 2017. Deals in oncology therapeutics market registered a decrease with 374 deals in Q2 2017, compared to 434 deals in Q1 2017. North America reported a decrease in the number of deals from 798 in Q1 2017 to 696 in Q2 2017.

Scope

  • Analysis of the market trends for the pharmaceutical industry in the global arena.
  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
  • Analysis of partnership and licensing deals based on clinical stage of development of products.
  • Summary of the pharmaceutical deals globally in the five quarters.
  • Information on the top deals happened in the pharmaceutical industry.
  • Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

  • Enhance your decision making capability in a more rapid and time sensitive manner.
  • Find out the major deal performing segments for investments in your industry.
  • Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
  • Identify companies that are aggressively looking to raise capital in the market
  • Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
  • Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
  • Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
  • Identify growth segments and opportunities in each region within the industry.
  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 5
  • 1.2 List of Figures 7

2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q2 2017 10

  • 2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q2 2017 10
  • 2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q2 2017 12
  • 2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q2 2017 13
  • 2.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q2 2017 14
    • 2.4.1 Becton, Dickinson to Raise USD10.5 Billion in Public Offering of Notes 14
    • 2.4.2 INC Research and inVentiv Health to Merge 14
    • 2.4.3 Thermo Fisher Scientific to Acquire Patheon 15
    • 2.4.4 Pamplona Capital Management to Acquire Parexel International for USD5 Billion 15
    • 2.4.5 Fresenius to Acquire Akorn 16

3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 17

  • 3.1 Pharmaceuticals & Healthcare, Global, M&A, Q2 2017 17
    • 3.1.1 Top M&A Deals in Q2 2017 18
    • 3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q2 2016 - Q2 2017 19
  • 3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q2 2017 20
    • 3.2.1 Top Initial Public Offerings in Q2 2017 21
    • 3.2.2 Top Secondary Offerings in Q2 2017 21
    • 3.2.3 Top PIPE Deals in Q2 2017 22
    • 3.2.4 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q2 2016 - Q2 2017 22
  • 3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q2 2017 24
    • 3.3.1 Top Venture Financing Deals in Q2 2017 25
    • 3.3.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q2 2017 25
    • 3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q2 2017 26
    • 3.3.5 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q2 2016 - Q2 2017 27
    • 3.3.6 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Q2 2016 - Q2 2017 28
    • 3.3.7 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q2 2016 - Q2 2017 29
  • 3.4 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q2 2017 30
    • 3.4.1 Top Private Equity Deals in Q2 2017 31
    • 3.4.2 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q2 2016 - Q2 2017 31

4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q2 2017 33

  • 4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q2 2017 33
  • 4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q2 2016 - Q2 2017 34
  • 4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2017 35
    • 4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q2 2017 36
    • 4.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q2 2017 36
    • 4.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q2 2017 36
  • 4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2016 - Q2 2017 37
  • 4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q2 2016 - Q2 2017 38
  • 4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q2 2016 - Q2 2017 39
  • 4.8 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2016 - Q2 2017 40

5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q2 2017 42

  • 5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q2 2017 42
  • 5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q2 2016 - Q2 2017 43
    • 5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q2 2017 44
    • 5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q2 2017 44
    • 5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q2 2017 45
  • 5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q2 2016 - Q2 2017 46
  • 5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q2 2016 - Q2 2017 47
  • 5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q2 2016 - Q2 2017 48
  • 5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q2 2016 - Q2 2017 49
  • 5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q2 2016 - Q2 2017 51

6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 53

  • 6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q2 2017 53
    • 6.1.1 Oncology - Deals of the Quarter 54
  • 6.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q2 2017 56
    • 6.2.1 Central Nervous System - Deals of the Quarter 57
  • 6.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q2 2017 59
    • 6.3.1 Infectious Disease - Deals of the Quarter 60
  • 6.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q2 2017 61
    • 6.4.1 Immunology - Deals of the Quarter 62
  • 6.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q2 2017 63
    • 6.5.1 Metabolic Disorders - Deals of the Quarter 64
  • 6.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q2 2017 66
    • 6.6.1 Cardiovascular - Deals of the Quarter 67
  • 6.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q2 2017 68
    • 6.7.1 Gastrointestinal - Deals of the Quarter 69
  • 6.8 Pharmaceuticals & Healthcare, Global, Hematological Disorders Deals, Q2 2017 70
    • 6.8.1 Hematological Disorders - Deals of the Quarter 71
  • 6.9 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q2 2017 73
    • 6.9.1 Respiratory - Deals of the Quarter 74
  • 6.10 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q2 2017 77
    • 6.10.1 .Dermatology - Deals of the Quarter 78

7 Deal Summary by Geography 79

  • 7.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q2 2017 79
    • 7.1.1 North America - Deals of the Quarter 80
  • 7.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q2 2017 82
    • 7.2.1 Europe - Deals of the Quarter 83
  • 7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q2 2017 84
    • 7.3.1 Asia-Pacific - Deals of the Quarter 85
  • 7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q2 2017 86
    • 7.4.1 Rest of the World - Deals of the Quarter 87

8 Pharmaceuticals & Healthcare, Global, Top Advisors 88

  • 8.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Q2 2016 - Q2 2017 88
  • 8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Q2 2016 - Q2 2017 89

9 Further Information 90

  • 9.1 Methodology 90
  • 9.2 About GlobalData 91
  • 9.3 Contact Us 91
  • 9.4 Disclosure information 91
  • 9.5 Disclaimer 92

List of Tables

1.1 List of Tables

  • Table 1: Pharmaceuticals & Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q2 2016 - Q2 2017 11
  • Table 2: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), Q2 2017 13
  • Table 3: Pharmaceuticals & Healthcare, Global, Top Deals, Q2 2017 14
  • Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 18
  • Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, Q2 2017 18
  • Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, , Q2 2016 - Q2 2017 19
  • Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), Q2 2016 - Q2 2017 21
  • Table 8: Pharmaceuticals & Healthcare, Global, Top Initial Public Offering Deals, Q2 2017 21
  • Table 9: Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q2 2017 21
  • Table 10: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q2 2017 22
  • Table 11: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$m), Q2 2016 - Q2 2017 23
  • Table 12: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 24
  • Table 13: Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q2 2017 25
  • Table 14: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), Q2 2017 26
  • Table 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q2 2016 - Q2 2017 27
  • Table 16: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 28
  • Table 17: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q2 2016 - Q2 2017 29
  • Table 18: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 30
  • Table 19: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, Q2 2017 31
  • Table 20: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q2 2016 - Q2 2017 32
  • Table 21: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 33
  • Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 34
  • Table 23: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q2 2016 - Q2 2017 35
  • Table 24: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payments and Deal Values (US$ m), Q2 2017 36
  • Table 25: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q2 2017 36
  • Table 26: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q2 2017 36
  • Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q2 2016 - Q2 2017 37
  • Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q2 2016 - Q2 2017 39
  • Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q2 2016 - Q2 2017 41
  • Table 30: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 42
  • Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payments and Deal Values (US$ m), Q2 2016 - Q2 2017 43
  • Table 32: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q2 2017 44
  • Table 33: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q2 2017 44
  • Table 34: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q2 2017 45
  • Table 35: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 46
  • Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (US$ m), Q2 2016 - Q2 2017 47
  • Table 37: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q2 2016 - Q2 2017 50
  • Table 38: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Values (US$ m), Q2 2016 - Q2 2017 52
  • Table 39: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 54
  • Table 40: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 57
  • Table 41: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 60
  • Table 42: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 62
  • Table 43: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 64
  • Table 44: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 67
  • Table 45: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 69
  • Table 46: Pharmaceuticals & Healthcare, Global, Hematological Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 71
  • Table 47: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 74
  • Table 48: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 78
  • Table 49: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 80
  • Table 50: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 83
  • Table 51: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 85
  • Table 52: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 87
  • Table 53: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 88
  • Table 54: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 89

List of Figures

1.2 List of Figures

  • Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$m), Q2 2016 - Q2 2017 10
  • Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), Q2 2017 12
  • Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), Q2 2017 13
  • Figure 4: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$m), Q2 2016 - Q2 2017 17
  • Figure 5: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, Q2 2016 - Q2 2017 19
  • Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 20
  • Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m), , Q2 2016 - Q2 2017 22
  • Figure 8: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 24
  • Figure 9: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), Q2 2017 25
  • Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), Q2 2017 26
  • Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q2 2016 - Q2 2017 27
  • Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 28
  • Figure 13: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 30
  • Figure 14: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q2 2016 - Q2 2017 31
  • Figure 15: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 33
  • Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 34
  • Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), Q2 2016 - Q2 2017 35
  • Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q2 2016 - Q2 2017 37
  • Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q2 2016 - Q2 2017 38
  • Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q2 2016 - Q2 2017 39
  • Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), Q2 2016 - Q2 2017 40
  • Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 42
  • Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2016 - Q2 2017 43
  • Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 46
  • Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), Q2 2016 - Q2 2017 47
  • Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, Q2 2016 - Q2 2017 48
  • Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), Q2 2016 - Q2 2017 49
  • Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2016 - Q2 2017 51
  • Figure 29: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 53
  • Figure 30: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 56
  • Figure 31: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 59
  • Figure 32: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 61
  • Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 63
  • Figure 34: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 66
  • Figure 35: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 68
  • Figure 36: Pharmaceuticals & Healthcare, Global, Hematological Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 70
  • Figure 37: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 73
  • Figure 38: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 77
  • Figure 39: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 79
  • Figure 40: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 82
  • Figure 41: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 84
  • Figure 42: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 86
  • Figure 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 88
  • Figure 44: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q2 2016 - Q2 2017 89
Back to Top